In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms

Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo reporting, we show that continuous MEKi with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Autores principales: Teh, Jessica L.F., Cheng, Phil F., Purwin, Timothy J., Nikbakht, Neda, Patel, Prem, Chervoneva, Inna, Ertel, Adam, Fortina, Paolo M., Kleiber, Ines, HooKim, Kim, Davies, Michael A., Kwong, Lawrence N., Levesque, Mitch P., Dummer, Reinhard, Aplin, Andrew E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858088/
https://ncbi.nlm.nih.gov/pubmed/29496664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0699
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares